ClinicalTrials.gg
Not yet recruitingNCT07940543Updated Nov 17, 2026

Construction of a Liver Metabolic Atlas in Biliary Atresia Based on Raman Spectroscopic Imaging

An observational study in Biliary Atresia, Choledochal Cyst and Intrahepatic Cholestasis, sponsored by Nanjing Children's Hospital. Not yet recruiting at 1 site in China. Open to participants aged 15 Days to 6 Months. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Nanjing Children's Hospital · Observational

How we know

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
80
Ages
15 Days to 6 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Biliary Atresia with a site in China — 7 open to participants now, 9 under way, 1 of them phase 3. Biliary Atresia · China.

Planned enrollment
9th of 10
80 · median 200
Started
2026
the only one that year
Observational
10 of 21
5 open now
Registered
21st of 21
by date
Lead sponsor
2 of 21
Nanjing Children's Hospital

Among the 21 studies in Biliary Atresia with a site in China, this one is the 9th largest by planned enrollment of the 10 observational ones that give a count, is the only one that started in 2026, is one of 10 observational ones, and was the 21st registered.

Biliary Atresia

78 studies on the registry are indexed under Biliary Atresia; 26 are open to participants now.

Browse Biliary Atresia studies →

Open to participants now

7 of the 21 studies in Biliary Atresia with a site in China are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 21 Biliary Atresia studies recruiting now, 3 (14%) set no upper age limit and 18 (86%) stop at 75 or younger; 21 take children under 18; 6 take healthy volunteers.

This study: 15 Days to 6 Months · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Biliary Atresia with a site in China, or all of them as a file.
02

Study summary

Biliary atresia (BA) is a severe infantile cholangiopathy characterized by progressive inflammation and fibrotic obliteration of the intra- and extrahepatic bile ducts. Although Kasai portoenterostomy can restore bile drainage, more than 50% of affected infants still progress to end-stage liver disease and require liver transplantation. BA is not merely a structural biliary obstruction but a complex liver disease involving cholestasis, oxidative stress, mitochondrial dysfunction, lipid peroxidation, bile acid metabolic disorders, and collagen deposition. Current clinical assessment relies mainly on serum liver function tests and semi-quantitative histological scoring, which cannot reveal the overall metabolic landscape or spatial heterogeneity of the liver. Raman imaging is a label-free, high-spatial-resolution molecular vibrational imaging technique that can simultaneously detect lipids, proteins, nucleic acids, glycogen, collagen, bilirubin, bile acids, and oxidative stress products. It has demonstrated metabolic phenotyping capability in tumor heterogeneity, organ development, and nonalcoholic fatty liver disease. However, the in situ spatial distribution of metabolites in BA liver-especially metabolic differences among portal, parenchymal, and centrilobular regions, the metabolic microenvironment around bile duct reaction foci, and metabolic boundaries of fibrous septa-remains unexplored by conventional metabolomics. Preliminary studies by our group have identified collagen deposition, oxidative stress, and bile acid metabolic abnormalities in BA liver. We hypothesize that BA liver undergoes coordinated metabolic reprogramming that forms characteristic Raman-capturable metabolic signatures, which may serve as novel tools for disease stratification and prognosis prediction. This study aims to construct a Raman-based liver metabolic atlas and evaluate its prognostic value.

Read the detailed description

Biliary atresia (BA) is a severe infantile cholangiopathy characterized by progressive inflammation and fibrotic obliteration of the intrahepatic and extrahepatic bile ducts. Kasai portoenterostomy can temporarily restore bile drainage, but more than 50% of affected infants still progress to end-stage liver disease and require liver transplantation. BA is not merely a structural biliary obstruction; it is a complex liver disease involving cholestasis, oxidative stress, mitochondrial dysfunction, lipid peroxidation, bile acid metabolic disorders, and collagen deposition. Current clinical assessment relies mainly on conventional serum liver function indices (ALT, AST, GGT, TBIL, DBIL, and TBA) and semi-quantitative histopathological scoring. These approaches cannot reveal the overall metabolic landscape or the spatial heterogeneity of the liver, resulting in a lack of systematic understanding of metabolic reprogramming in BA.

Raman imaging is a label-free molecular vibrational spectroscopic imaging technique based on inelastic scattering. It can simultaneously detect chemical bond information from lipids, proteins, nucleic acids, glycogen, collagen, bilirubin, bile acids, and oxidative stress products without exogenous probes or labels, and it offers high spatial resolution and non-destructive detection. Raman imaging has demonstrated metabolic phenotyping capability in tumor metabolic heterogeneity, organ development, and nonalcoholic fatty liver disease. Previous studies suggest that BA patients have multiple metabolic abnormalities, including bile acid metabolic disorders. However, the in situ spatial distribution of metabolites in BA liver-especially metabolic differences among portal, parenchymal, and centrilobular regions, the metabolic microenvironment around bile duct reaction foci, and the metabolic boundaries of fibrous septa-cannot be obtained by conventional metabolomics, representing an important research gap. Raman imaging has the unique advantage of "spatial metabolomics," enabling metabolic information to be localized to specific pathological structures and providing a new dimension for understanding the relationship between intrahepatic metabolic heterogeneity and disease progression. Preliminary studies by our group have identified collagen deposition, oxidative stress, and bile acid metabolic abnormalities in BA liver. We hypothesize that BA liver undergoes coordinated metabolic reprogramming during pathological progression, forming characteristic Raman-capturable metabolic signatures that can comprehensively quantify multidimensional metabolic features and serve as novel tools for disease stratification and prognosis prediction.

Briefly, this single-center prospective observational study will enroll 60 infants with BA undergoing Kasai portoenterostomy and 20 age-matched controls (10 choledochal cysts and 10 intrahepatic cholestasis without BA). Intraoperative liver tissues will be collected and analyzed by confocal Raman imaging with near-infrared excitation and large-area multi-region scanning. HE and Masson staining and image registration will link spectral pixels to histological structures. A full-spectrum database will be established, and spectral unmixing will generate spatial metabolic heat maps, regional metabolic fingerprints, and metabolic gradients. Raman-derived parameters will be integrated with clinical and pathological data to develop a metabolic classification and a prognostic model for native liver survival using Cox and LASSO regression. Participants will be followed for at least 3 years. Primary outcomes are jaundice clearance and native liver survival after Kasai surgery; secondary outcomes include postoperative biochemical indices and liver stiffness. The study poses minimal risk, involves no new drugs or devices, and will be conducted with informed consent and ethical approval.

03

Conditions studied

  • Biliary Atresia
  • Choledochal Cyst
  • Intrahepatic Cholestasis

Keywords

  • Stimulated Raman
  • Biliary atresia
  • Metabolism
04

Who can participate

Ages eligible
15 Days to 6 Months
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with biliary atresia and undergoing Kasai surgery.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Obtain the from the parents of the patients; 2. Children diagnosed with biliary atresia and undergoing Kasai surgery; 3. The control group consists of children with age-matched choledochal cysts and those with intrahepatic cholestasis excluding biliary atresia; 4. The medical records are complete.

Exclusion criteria

Exclusion Criteria:

  • 1. Without obtaining the of the parents; 2. Children diagnosed with biliary atresia through cholangiography but not undergoing the Kasai surgery; 3. Children with incomplete medical records.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
80 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes

Groups and cohorts

  • Biliary atresia

    Biliary atresia patients who undergo Kasai surgery

    Diagnostic Test: Stimulated Raman Test

Interventions

  • Diagnostic testStimulated Raman Test

    All the intraoperative liver biopsy tissues of the participants will undergo Raman imaging to assess the metabolic status of the liver tissues.

06

What researchers measure

Primary outcomes

  1. Juandice clearance

    Serum direct bilirubin \< 2mg/dL

    Time frame: 3 months post Kasai augery

Secondary outcomes

  1. Native liver survival

    Native liver survival without liver transplantation or death

    Time frame: 2 years post Kasai augery

07

Study locations

1 site
  • Nanjing Children's Hospital
    Nnajing, China
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data (including demographic, clinical, and outcome variables) collected during the trial will be made available to qualified researchers.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Data will become accessible:Starting Date: 6 months after study completion;End Date: Minimum 5 years after publication.

Access criteria: Access to IPD requires submitting a formal research proposal (including hypothesis/analysis plan, ethical approval proof if applicable, and conflict of interest disclosure) to the investigator's email, along with a signed Data Use Agreement (DUA) prohibiting re-identification, commercial use, and redistribution.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Mar 2027, 4 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2026
First posted
Nov 17, 2026
StartEst.
Nov 10, 2026
Primary completionEst.
Mar 10, 2027
CompletionEst.
Sep 30, 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07940543
Lead sponsor
Nanjing Children's Hospital
Responsible party
Weibing Tang (Chief of Department of neonatal surgery, Nanjing Children's Hospital) — Principal investigator
First posted
Nov 17, 2026
Start date
Nov 10, 2026 (estimated)
Primary completion
Mar 10, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Zequan Ding
Contact
dingzqcn@163.com
+8613057659508

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion